Global Liver Fibrosis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Liver Fibrosis Market Overview

The Liver Fibrosis Market was valued at USD 25.24 billion in 2025 and is projected to reach USD 59.43 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. The market is witnessing steady expansion driven by the rising global burden of chronic liver diseases, increasing prevalence of hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and growing alcohol-related liver disorders. Advancements in non-invasive diagnostic technologies and improved awareness regarding early-stage liver disease detection are further supporting market growth.

The increasing demand for early and accurate fibrosis assessment, coupled with a shift from invasive liver biopsies toward imaging-based and serum biomarker diagnostic methods, is accelerating adoption across healthcare systems. In addition, expanding pharmaceutical R&D for anti-fibrotic therapies and growing screening initiatives in high-risk populations are strengthening market penetration. The integration of AI-enabled imaging and elastography solutions in clinical practice is further enhancing diagnostic precision and driving the transition toward more efficient liver disease management.

Key Market Trends & Insights

• North America dominated the Liver Fibrosis Market with the largest revenue share of 36.42% in 2025, supported by high disease prevalence, advanced diagnostic infrastructure, and strong adoption of non-invasive liver assessment technologies.
• The Chronic Liver Diseases segment led the market with a 44.36% share in 2025, driven by the high global burden of long-term liver damage caused by alcohol abuse, viral infections, and metabolic disorders.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.6% from 2026 to 2033, fueled by rising incidence of hepatitis infections, growing awareness of early-stage liver disease detection, and expanding healthcare infrastructure in China, India, and Japan.
• Nonalcoholic Steatohepatitis are the fastest-growing condition type, projected to register a CAGR of 8.2%, reflecting the surge in obesity, diabetes, and sedentary lifestyles globally.
• The Hepatotropic Drug segment dominated the treatment category with a 39.62% revenue share in 2025, led by its widespread use in managing liver inflammation, fibrosis progression, and hepatocellular protection.
• Oral accounted for 57.84% of the market, preferred by patient convenience, high compliance, and widespread use of oral hepatoprotective and anti-fibrotic medications
• The Nonsurgical Tests segment is the fastest-growing diagnosis category, with a CAGR of 8.0%, driven by the rising demand for blood-based biomarkers and AI-integrated diagnostic panels.

Market Size & Forecast

• Global Market Value (2025): USD 25.24 Billion
• Expected Market Value (2033): USD 59.43 Billion
• Forecast CAGR (2026–2033): 11.30%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Liver Fibrosis Market Segmentation

Liver Fibrosis Market Trends

Trend: Rising Shift Toward Non-Invasive Diagnostic Technologies

Healthcare providers are increasingly adopting non-invasive methods such as transient elastography, magnetic resonance elastography, and serum biomarker panels to assess liver fibrosis, reducing reliance on invasive biopsy procedures. These technologies improve patient compliance, enable repeatable monitoring of disease progression, and support earlier detection in high-risk populations. Integration of digital imaging systems and AI-based interpretation tools is further enhancing diagnostic accuracy and workflow efficiency in clinical hepatology settings, while improving large-scale screening capabilities across hospitals and diagnostic centers. for instance, FibroScan adoption in chronic hepatitis management programs and AI-assisted elastography tools in tertiary care hospitals.

Liver Fibrosis Market Dynamics

Key Market Driver: Rising Prevalence of Chronic Liver Diseases and Metabolic Disorders

The increasing global incidence of non-alcoholic fatty liver disease (NAFLD), hepatitis B and C infections, alcohol-related liver disease, and obesity-linked metabolic syndrome is driving strong demand for early fibrosis detection and monitoring solutions. Growing awareness among clinicians and patients regarding disease progression from fibrosis to cirrhosis and liver failure is further accelerating diagnostic uptake. Expanding national screening programs and improved access to liver function testing in emerging healthcare systems are also supporting market growth. for instance, national hepatitis elimination programs and obesity-linked liver screening initiatives in urban hospitals.

Key Restraint/Challenge: : High Cost and Limited Accessibility of Advanced Diagnostic Systems

A major challenge in the liver fibrosis market is the high cost of advanced diagnostic technologies such as MRI elastography, high-end ultrasound systems, and AI-integrated imaging platforms, which limits adoption in low- and middle-income healthcare settings. Limited reimbursement coverage for non-invasive fibrosis tests and uneven distribution of specialized hepatology infrastructure further restrict widespread usage. In addition, lack of trained professionals for operating advanced imaging systems impacts diagnostic consistency and scalability. for instance, restricted access to elastography systems in rural diagnostic centers and limited insurance reimbursement for advanced liver imaging tests.

Key Market Opportunity: Expansion of AI-Driven Precision Diagnostics and Point-of-Care Testing

The integration of artificial intelligence with imaging and biomarker-based diagnostics presents a significant opportunity for improving early detection, risk stratification, and disease monitoring in liver fibrosis patients. Development of portable point-of-care testing devices and cloud-connected diagnostic platforms is enabling faster and more accessible liver health assessment outside tertiary hospitals. Increasing collaborations between diagnostic companies and digital health firms are accelerating innovation in predictive analytics and personalized disease management models. for instance, AI-enabled fibrosis staging platforms and portable liver stiffness measurement devices used in outpatient clinics and community health camps.

Liver Fibrosis Market Scope

The liver fibrosis market is segmented on the basis of condition, treatment, route of administration, diagnosis, end-users, and distribution channel.

• By Condition

On the basis of condition, the Liver Fibrosis Market is segmented into chronic liver diseases, hepatitis C, and nonalcoholic steatohepatitis (NASH). The Chronic Liver Diseases segment dominated the market with a 44.36% share in 2025, driven by the high global burden of long-term liver damage caused by alcohol abuse, viral infections, and metabolic disorders. This segment benefits from continuous patient monitoring requirements and frequent diagnostic testing across healthcare systems. Increasing progression rates from fibrosis to cirrhosis further strengthen demand for early detection tools. Expanding hospital-based screening programs and routine liver function testing also support its dominance. Rising awareness among clinicians regarding disease staging is improving diagnosis rates. The segment remains central due to its broad clinical classification covering multiple underlying causes.

The Nonalcoholic Steatohepatitis (NASH) segment is expected to witness the fastest growth at a CAGR of 8.2% from 2026 to 2033, driven by rising obesity, diabetes, and sedentary lifestyles globally. NASH is increasingly recognized as a major precursor to advanced liver fibrosis and cirrhosis, leading to higher screening rates. Growing pharmaceutical R&D activity targeting NASH-specific therapies is further accelerating diagnostic demand. Improved awareness among patients and physicians is enabling earlier intervention. Expanding metabolic disorder clinics and liver health programs are supporting adoption. Increasing focus on lifestyle-related liver diseases is further boosting segment growth.

• By Treatment

On the basis of treatment, the market is segmented into PPAR-alpha agonists, ACE inhibitors, hepatotropic drugs, and others. The Hepatotropic Drug segment dominated the market with a 39.62% share in 2025, owing to its widespread use in managing liver inflammation, fibrosis progression, and hepatocellular protection. These drugs are commonly prescribed across hospital settings for both chronic and acute liver conditions. Strong clinical adoption and availability of multiple therapeutic options contribute to segment leadership. Continuous research in liver-targeted pharmacotherapy is expanding usage. Physicians prefer hepatotropic drugs as first-line supportive therapy in fibrosis management. The segment benefits from established treatment protocols in hepatology care.

The PPAR-alpha Agonists segment is projected to grow at the fastest CAGR of 8.5% from 2026 to 2033, driven by increasing research into metabolic and anti-fibrotic mechanisms. These drugs show strong potential in reducing liver fat accumulation and inflammation in NASH-related fibrosis. Expanding clinical trials and regulatory interest in metabolic liver disease treatments are supporting growth. Pharmaceutical companies are investing heavily in targeted nuclear receptor therapies. Rising demand for disease-modifying therapies is further accelerating adoption. The segment is expected to benefit significantly from future approvals for NASH-specific indications.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral, parenteral, and others. The Oral segment dominated the market with a 57.48% share in 2025, driven by patient convenience, high compliance, and widespread use of oral hepatoprotective and anti-fibrotic medications. Oral drugs are preferred for long-term management of chronic liver conditions. Their ease of administration makes them suitable for outpatient and homecare settings. Strong availability of oral formulations across therapeutic classes supports dominance. Physicians favor oral therapy for maintenance treatment and early-stage fibrosis cases. The segment benefits from continuous pharmaceutical pipeline expansion.

The Parenteral segment is expected to register the fastest growth at a CAGR of 7.8% from 2026 to 2033, driven by increasing use of injectable biologics and hospital-based acute care treatments. Parenteral administration is preferred in severe fibrosis and advanced liver disease cases requiring rapid therapeutic action. Growing development of injectable anti-fibrotic agents is further supporting demand. Hospital admissions for liver complications are increasing globally. Rising use of intravenous therapies in critical care settings is also contributing to growth. The segment benefits from advancements in biologic drug delivery systems.

• By Diagnosis

On the basis of diagnosis, the market is segmented into nonsurgical tests, transient elastography, liver biopsy, and others. The Transient Elastography segment dominated the market with a 42.91% share in 2025, driven by its non-invasive nature, accuracy, and rapid assessment of liver stiffness. It is widely adopted as an alternative to liver biopsy in routine clinical practice. Increasing availability of FibroScan and similar technologies is strengthening adoption. Hospitals and diagnostic centers prefer it for repeat monitoring of fibrosis progression. Growing awareness of early liver disease detection supports its usage. The segment benefits from strong clinical validation and guideline recommendations.

The Nonsurgical Tests segment is projected to grow at the fastest CAGR of 8.0% from 2026 to 2033, driven by rising demand for blood-based biomarkers and AI-integrated diagnostic panels. These tests offer cost-effective and minimally invasive alternatives for large-scale screening. Expanding use in primary care settings is improving early detection rates. Continuous innovation in biomarker discovery is enhancing diagnostic accuracy. Increasing adoption in population-based screening programs is further accelerating growth. The segment benefits from scalability and ease of deployment.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, specialty clinics, homecare, and others. The Hospitals segment dominated the market with a 59.21% share in 2025, due to their advanced diagnostic infrastructure and availability of specialized hepatology departments. Hospitals serve as the primary centers for fibrosis diagnosis and disease management. High patient inflow and access to advanced imaging technologies strengthen dominance. Integration of multidisciplinary liver care teams supports comprehensive treatment approaches. Hospitals also conduct large-scale screening and clinical trials. The segment benefits from strong reimbursement frameworks.

The Specialty Clinics segment is expected to witness the fastest growth at a CAGR of 7.9% from 2026 to 2033, driven by increasing preference for focused liver care and outpatient-based diagnosis. These clinics offer specialized expertise in hepatology and metabolic liver diseases. Rising awareness and early diagnosis trends are increasing patient visits. Lower treatment costs compared to hospitals support adoption. Expansion of private healthcare infrastructure is further accelerating growth. The segment benefits from personalized and continuous patient monitoring.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The Hospital Pharmacy segment dominated the market with a 46.37% share in 2025, driven by high prescription volumes for liver disease treatments within hospital settings. Immediate drug availability for inpatients and outpatients supports dominance. Strong integration with hospital-based diagnostic and treatment workflows enhances efficiency. Physicians prefer centralized dispensing for better treatment control. The segment benefits from high institutional trust and regulated supply chains. Increasing hospital admissions for chronic liver diseases further strengthens its position.

The Online Pharmacy segment is projected to grow at the fastest CAGR of 8.3% from 2026 to 2033, driven by rising digital health adoption and increasing demand for home delivery of chronic disease medications. Patients with long-term liver conditions prefer convenient refill options through e-pharmacy platforms. Growing penetration of smartphones and telemedicine is supporting expansion. Discounts and subscription-based medication models are increasing adoption. Regulatory improvements in digital drug sales are further boosting growth. The segment benefits from expanding healthcare digitization trends.

Liver Fibrosis Market Regional Analysis

North America dominated the Liver Fibrosis Market with the largest revenue share of 36.42% in 2025, supported by high disease prevalence, advanced diagnostic infrastructure, and strong adoption of non-invasive liver assessment technologies. The region also benefits from well-established screening programs, significant R&D investments in hepatology, and early integration of AI-enabled imaging and elastography systems in clinical practice. Increasing focus on early disease detection, rising obesity-related liver disorders, and growing availability of advanced diagnostic tools continue to strengthen North America’s leadership position in the global market.

U.S. Liver Fibrosis Market Insight

The U.S. liver fibrosis market is witnessing strong growth due to high prevalence of nonalcoholic fatty liver disease (NAFLD), hepatitis infections, and alcohol-related liver disorders, along with advanced diagnostic infrastructure and strong R&D activity. The country’s mature healthcare ecosystem, coupled with widespread adoption of non-invasive diagnostic technologies such as transient elastography and AI-enabled imaging, is driving demand across hospitals and specialty clinics. In addition, increasing focus on early disease detection, rising obesity rates, and growing clinical trials for anti-fibrotic therapies are accelerating market adoption across the region.

Europe Liver Fibrosis Market Insight

The Europe liver fibrosis market remains a major contributor to global revenue, driven by strong government healthcare systems, structured screening programs, and high awareness of chronic liver disease management. The widespread use of non-invasive diagnostic tools in hospitals, along with growing adoption of advanced imaging and biomarker-based testing, is supporting market expansion across the region. Increasing investments in hepatology research, strict clinical guidelines for liver disease monitoring, and rising prevalence of metabolic disorders continue to enhance adoption of fibrosis diagnostics throughout Europe.

U.K. Liver Fibrosis Market Insight

The U.K. liver fibrosis market is experiencing steady growth, supported by rising prevalence of alcohol-related liver disease and metabolic disorders, along with increasing adoption of early diagnostic screening programs. Growing investments in NHS-led liver disease initiatives and expansion of non-invasive testing infrastructure are contributing to market growth. Furthermore, integration of AI-based diagnostic tools, improved access to transient elastography, and rising focus on preventive healthcare are strengthening the U.K.’s position in liver disease management.

Germany Liver Fibrosis Market Insight

The Germany liver fibrosis market is expanding steadily due to strong clinical research capabilities, advanced hospital infrastructure, and increasing adoption of precision diagnostic technologies. Hospitals and diagnostic centers are increasingly utilizing elastography and biomarker-based tests for early detection and disease staging. Continuous innovation in medical imaging, strong pharmaceutical research activity in hepatology, and government support for chronic disease management are further driving market growth in Germany.

Asia-Pacific Liver Fibrosis Market Insight

The Asia-Pacific liver fibrosis market is expected to witness rapid growth, driven by rising incidence of hepatitis B and C, increasing cases of NAFLD, and expanding healthcare infrastructure across countries such as China, India, and Japan. Growing awareness regarding early diagnosis, improving access to diagnostic technologies, and rising government initiatives for liver disease screening are supporting regional market expansion. In addition, increasing investments in hospital infrastructure and growing adoption of non-invasive diagnostic solutions are accelerating market growth across the region.

Japan Liver Fibrosis Market Insight

The Japan liver fibrosis market is witnessing consistent growth due to high prevalence of metabolic disorders, strong focus on preventive healthcare, and advanced diagnostic capabilities. Hospitals and research institutes are increasingly adopting transient elastography and AI-integrated imaging systems for accurate disease assessment and monitoring. Moreover, the country’s emphasis on early-stage diagnosis, combined with technological innovation in medical imaging and strong healthcare infrastructure, is further contributing to market growth.

China Liver Fibrosis Market Insight

The China liver fibrosis market is growing rapidly, driven by a high burden of hepatitis infections, increasing obesity rates, and expanding healthcare access across urban and rural regions. Government-led liver disease screening programs, rising adoption of non-invasive diagnostic technologies, and growing investment in hospital infrastructure are significantly boosting market demand. In addition, rapid advancements in medical imaging, increasing awareness of chronic liver disease, and expanding pharmaceutical R&D activities are positioning China as one of the fastest-growing markets globally.

Liver Fibrosis Market Share

The liver fibrosis industry is primarily led by well-established companies, including:

• Gilead Sciences, Inc. (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• Siemens Healthineers AG (Germany)
• AbbVie Inc. (U.S.)
• Bristol Myers Squibb Company (U.S.)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Boehringer Ingelheim International GmbH (Germany)
• GE HealthCare (U.S.)
• FUJIFILM Holdings Corporation (Japan)
• Echosens (France)
• Intercept Pharmaceuticals, Inc. (U.S.)
• Madrigal Pharmaceuticals, Inc. (U.S.)
• Ipsen S.A. (France)
• BioVie Inc. (U.S.)

Latest Developments in Liver Fibrosis Market

• In March 2024, the U.S. Food and Drug Administration (FDA) approved Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, marking the first-ever approved therapy directly targeting fibrosis progression in this patient population. This milestone significantly advanced the liver fibrosis treatment landscape by validating a disease-modifying therapeutic approach and accelerating global research into anti-fibrotic drug development
• In December 2023, major global hepatology societies including AASLD and EASL officially replaced the term nonalcoholic steatohepatitis (NASH) with metabolic dysfunction-associated steatohepatitis (MASH), reflecting the metabolic origins of the disease responsible for liver fibrosis progression. This reclassification improved disease understanding, standardized clinical trial terminology, and enhanced regulatory alignment across drug development programs
• In June 2023, the American Association for the Study of Liver Diseases (AASLD) released updated clinical guidance recommending non-invasive tools such as FIB-4 scoring and transient elastography as first-line approaches for liver fibrosis assessment. This update reduced dependence on invasive liver biopsy procedures and reinforced early detection and monitoring strategies for chronic liver disease
• In September 2022, Madrigal Pharmaceuticals announced positive Phase 3 MAESTRO-NASH clinical trial results for resmetirom, demonstrating significant improvement in liver fibrosis and resolution of steatohepatitis compared to placebo. This clinical breakthrough played a key role in advancing regulatory approval pathways and strengthening confidence in disease-modifying therapies for NASH-related fibrosis
• In April 2021, multiple peer-reviewed studies published in leading journals, including The Lancet Gastroenterology & Hepatology, validated the effectiveness of non-invasive fibrosis scoring systems such as FIB-4 and NAFLD fibrosis score for routine clinical use. These findings supported reduced reliance on liver biopsy for initial staging and improved accessibility of fibrosis assessment in primary and secondary care settings

SKU-54747